Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Gasparetto C, Schiller GJ, Tuchman SA, Callander NS, Baljevic M, Lentzsch S, Rossi AC, Kotb R, White D, Bahlis NJ, Chen CI, Sutherland HJ, Madan S, LeBlanc R, Sebag M, Venner CP, Bensinger WI, Biran N, Ammu S, Ben-Shahar O, DeCastro A, Van Domelen D, Zhou T, Zhang C, Bentur OS, Shah J, Shacham S, Kauffman M, Lipe B. Gasparetto C, et al. Among authors: shah j. Br J Cancer. 2022 Mar;126(5):718-725. doi: 10.1038/s41416-021-01608-2. Epub 2021 Nov 20. Br J Cancer. 2022. PMID: 34802051 Free PMC article. Clinical Trial.
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. Kumar SK, et al. Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Leukemia. 2012. PMID: 21799510 Free PMC article.
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC. Iyer SP, et al. Among authors: shah j. Br J Haematol. 2014 Nov;167(3):366-75. doi: 10.1111/bjh.13056. Epub 2014 Aug 19. Br J Haematol. 2014. PMID: 25139740 Free article. Clinical Trial.
Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.
Rifkin RM, Abonour R, Terebelo H, Shah JJ, Gasparetto C, Hardin J, Srinivasan S, Ricafort R, Nagarwala Y, Durie BG. Rifkin RM, et al. Among authors: shah jj. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):368-76. doi: 10.1016/j.clml.2014.12.002. Epub 2014 Dec 11. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25617035
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ. Usmani SZ, et al. Among authors: shah jj. Blood Cancer J. 2015 Aug 7;5(8):e334. doi: 10.1038/bcj.2015.62. Blood Cancer J. 2015. PMID: 26252787 Free PMC article. No abstract available.
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Shah JJ, et al. Blood. 2015 Nov 12;126(20):2284-90. doi: 10.1182/blood-2015-05-643320. Epub 2015 Sep 17. Blood. 2015. PMID: 26384354 Free PMC article. Clinical Trial.
4,143 results